Inhibikase Therapeutics, Inc. IKT Q1 2025 Annual earnings
Reported May 14, 2025 · Before market open
EPS estimate-$0.11
Next report
Aug 13, 2026 (in a month)EPS estimate-$0.09
Versus estimates
Diluted EPS
Ask the moment Inhibikase Therapeutics, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Inhibikase Therapeutics, Inc. report Q1 2025 earnings?
- Inhibikase Therapeutics, Inc. (IKT) reported Q1 2025 earnings on May 14, 2025 before market open.
- What were Inhibikase Therapeutics, Inc.'s Q1 2025 revenue and EPS?
- Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.15 for Q1 2025.
- Did Inhibikase Therapeutics, Inc. beat estimates in Q1 2025?
- EPS missed the consensus estimate of $-0.11 by $0.04.
- How did Inhibikase Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, diluted EPS grew 79.5% from $-0.73.
- Where can I find Inhibikase Therapeutics, Inc.'s Q1 2025 SEC filings?
- You can read the 10-K/A periodic report (0000950170-25-058693) directly on SEC EDGAR. The filing index links above go to sec.gov.